Cuprina Holdings announces 1-for-8 Share Consolidation
Rhea-AI Summary
Cuprina Holdings (Nasdaq:CUPR) will implement a 1-for-8 share consolidation of its Class A and Class B ordinary shares, effective on or around May 27, 2026. Post-consolidation, Class A shares will continue trading on Nasdaq under symbol CUPR with new CUSIP G2592E110.
The action aims to help Cuprina regain compliance with Nasdaq Rule 5550(a)(2) and maintain its listing. Every 8 shares at par value US$0.001 will convert into 1 share at par value US$0.008, with fractional shares rounded up. Board approval occurred on April 21, 2026 and shareholder approval on May 14, 2026.
AI-generated analysis. Not financial advice.
Positive
- 1-for-8 share consolidation to support Nasdaq listing compliance
- Board approved consolidation on April 21, 2026
- Shareholders approved consolidation on May 14, 2026
- Fractional shares rounded up to the next whole share
Negative
- Minor ownership changes may occur from fractional share adjustments
Key Figures
Market Reality Check
Peers on Argus
CUPR was up 5.4% while sector peers showed mixed moves and only FEMY appeared in momentum scanners, suggesting a stock-specific reaction to the share consolidation news rather than a broad Healthcare move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Regulatory milestone | Positive | +8.1% | Saudi SFDA classification for MEDIFLY and advisory board expansion. |
| Dec 09 | Earnings & outlook | Negative | -6.6% | Six‑month results with low revenue, loss, and cautious 2026 projections. |
| Nov 28 | Nasdaq compliance notice | Negative | +1.5% | Nasdaq minimum bid price deficiency notification and compliance timelines. |
In recent news, price moves mostly aligned with sentiment, with only the Nasdaq deficiency notice showing a mild positive divergence.
Over the last few quarters, Cuprina has combined regulatory milestones with capital markets challenges. A Nov 28, 2025 Nasdaq minimum-bid deficiency notice highlighted listing risk. The Dec 9, 2025 earnings release showed small revenues and ongoing losses, while projecting initial 2026 revenue growth. On Mar 11, 2026, the company reported a Saudi SFDA classification and advisory board expansion. Today’s 1-for-8 share consolidation directly follows that deficiency notice, aiming to address the minimum bid issue.
Market Pulse Summary
This announcement outlines a 1-for-8 share consolidation approved by the board and shareholders to address Nasdaq Rule 5550(a)(2) minimum bid requirements and preserve the Nasdaq Capital Market listing. It follows a prior Nasdaq deficiency notice and broader capital-structure changes detailed in recent 6-K filings. Investors may monitor execution of the consolidation around May 27, 2026, subsequent financing activity, and how the adjusted share price trades relative to the $0.90 200-day moving average and prior news flow.
Key Terms
cusip technical
nasdaq marketplace rule 5550(a)(2) regulatory
AI-generated analysis. Not financial advice.
SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares (“Class A Ordinary Shares”) and Class B ordinary shares (“Class B Ordinary Shares”) (the "Share Consolidation"), effective on or around May 27, 2026.
Beginning with the opening of trading on or around May 27, 2026, the Company's Class A Ordinary Shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol " CUPR ", but under a new CUSIP number of G2592E110. The objective of the Share Consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market. Upon the effectiveness of the Share Consolidation, every eight (8) issued and outstanding Class A ordinary shares, par value US
The Share Consolidation was approved by the Company's board of directors on April 21, 2026 and its shareholders during its annual general meeting held on May 14, 2026.
“This action is an important step toward maintaining our Nasdaq listing and enhancing the Company’s long‑term financial flexibility,” said Cuprina Chief Executive Officer David Quek. “This approval reflects our shareholders’ support for strengthening Cuprina’s capital markets position as we continue advancing our biomedical and collagen‑based technology portfolio.”
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: ir@skylineccg.com
